Rezolute, Inc.
RZLT
Rezolute, Inc. ( Rezolute , the Company , we or us ) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism ( HI ). Summary of Clinical Assets Ersodetug Our lead clinical asset, ersodetug, is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$78M
▼ -4.3% YoY
Op. Margin
–
ROIC
-59.88%
▼ -5.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$66M
▲ +6.4% YoY
Op. Cash Flow (TTM)
-$66M
▲ +6.4% YoY
Net Debt
-$89M
Net Cash Position
Cash & Equiv.
$90M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with RZLT
Held by ETFs
RZLT is in 13 US ETFs. The largest of them, with RZLT's weight in each:
Rezolute (RZLT) in two numbers
Questions about Rezolute
Does Rezolute (RZLT) pay a dividend?
No. Rezolute (RZLT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 2 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in RZLT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RZLT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.